Member Info for amones

Thank you both for posting this here .

“The regulator also urged listed companies to bolster their value through share buybacks, stock purchases by major shareholders, regular dividend payouts and merges and acquisitions…”

Precisely, what we have been shouting from this messaging platform for many days!

What made the dead cat to jump? Trade volume of 7 million HKse. Has there been any significant news?

Pencil, it is just a hypothetical question.

I don’t have much knowledge about such complex topics.

(It’s a trivial doubt and I want to stress that it is not specifically about any company.)

Imagine a public listed company where the management has control over majority percentage of the shares, or, held by people and firms linked to the company. Can the management make use of poor market condition and enforce a compulsory buy back of ALL shares held by private and institutional investors and go private? Will it be legally allowed to do so as per stock exchanges’ (for example LSE/ NYSE/HKSE) rules and regulations.

I know it sounds illogical. Thanks if anybody able to clarify.

Hope one or two clever strategists working for bigger pharmas are watching today’s news as well as the pipeline.

Is there a similar online chat forum for HK shareholders to express their concerns and views?On an average, 3 million shares are traded daily at HKSE. What factors might be encouraging buyers over there to buy into this stock?

Has anyone received a reply from the ir department? Luckily, another weekend….

During Mr Hogg’s period, HCM used to get very good coverage in the financial sections of the press, with it’s stock price always in a healthy range. Markets used to treat the company fairly due to its decent pipeline. Now, the picture entirely different. The company has progressed very well with R&D, successfully getting approval for its drug candidates and marketing the same. Also, company has made alliances with other major players in the field resulting in significant royalties. While continuing to do productive progress and having no debts (correct me if I’m wrong) , it has failed to bring cheers to the investors. Share price is less than half its value 2 years ago and has fallen more than 30% since the beginning of the new year. The least, the management could do to help is to release a statement, whether they are ( /are not ) able to see any reason/s for decline in the market valuation.

Absence of a dedicated CEO seems to be the matter.

Hoping to see better days ahead!

One concern is about the rapid decline in the sp despite all the good achievements, including marketing a product in US market and also, impending outcome of application for approval for the same drug in Japan and Europe (plus many more). Over the last 3 weeks, sp has fallen by a quarter and the management is yet to say anything.

Regarding getting a reply from the company- 3 years ago, Mr Hogg, (then CEO), had replied to me, in detail, to an email enquiry arising from discussion on this board. He had taken time to respond a private investor’s query. However, I did not receive any response to another email to the investor relations, an year and half age. (Mr Hogg had retired by that time). Pencil , please inform other users of this bb If you get a response from the ir.

Luckily, it’s weekend and a pause for the agonising slump in the share price and diminishing market value. Regarding getting any kind of response from i.r, good luck to those trying to contact.

Appears outright deliberate act. Is there any reason for this decline this share is experiencing?

After having sold its shares in public offering, 3 years ago at HKSE, more than twice the present price, at what “attractive” price would the company be willing to buy back?

A great opportunity for a larger company to acquire

It was mentioned in one of the recent messages, that the company was working towards “safeguarding investors’ interests”. No sign of any such activity. On the other hand, market makers have acquired a freehand to treat this share as they wish. What exactly is happening? Really miserable feeling to watch this kind of decline in the sp, while the company is making good progress in developing and marketing new therapies for oncological and immunological conditions.

Has the management got to say anything about this poor sp? Finally, being remotely helpful, can this low low valuation trigger interest in M&A activity?

ITP is one of the haematological indications. Www search also brings up articles and news items mentioning many other immunological and haematological malignant conditions. It would have helped us if the company reiterates which are the conditions where Savlo is being developed as a useful therapy .

There must be much wider market for Sovleplenib as it has been developed for treating autoimmune conditions and haematological malignancies like lymphomas. It will be interesting to watch if the company can get another major player to collaborate, if required.

First piece of good news for the new year!

NMPA has accepted NDA for Sovleplenib for treatment of adult patients with primary immune thrombocytopenia, for review and granted priority review. As we are aware, HCM has been developing Sovleplenib for the treatment of hematological malignancies and immune diseases.

In case, management has any genuine intention of safeguarding investors’ interests, it is not yet been made visible. Rather, the short sellers have been playing the market, fearlessly. Even after the Takeda deal (worth a third of the market value of the company), share price has failed to recover. No news of new fund holders/ institutions showing interest.

Hope 2024 will bring back the long last shine to the sp. In the mean while, investors have to remain philosophical for this company working hard to develop new therapies to patients diagnosed with serious health conditions.

Is the majority holder interested, at all, in receiving an offer, irrespective of what other, institutional and private, investors’ wishes?

As a minnow holder, I am interested to see an offer price!!

in comparison to those two chinese companies, where does hcm stand?

it is quite well established, successfully developed three oncology therapies which are already in the market. fru*****inib has recently become available in the united states and awaiting approval in europe and japan. plus a pipeline consisting of various ongoing phase2 and phase 3 studies for a number of clinical applications.

has hutchmed already become too big to be merged with another major phama? if at all possible, what might be an appropriate offer price?

First option, if ever happens, would be nice for long time holders.

AZN acquiring Gracell Biotechnologies, a Chinese pharmaceutical company for $1 billion. Gracell sp has raisen 30%. Fingers crossed!

One can only assume that there’s a desperate attempt in the market to keep the sp down, what ever the progress may be.